Nucleotides from bacterial-yeast fermentation as pharmacologically active feed supplements: immune mechanisms, clinical evidence and practical guidelines
Scientific Messenger of LNU of Veterinary Medicine and Biotechnology · 16.11.2026 · 28 (122) · 10-14
DOI: 10.32782/nvlvet12202 ↗Kurz gefasst
Leitlinie in der Zeitschrift Scientific Messenger of LNU of Veterinary Medicine and Biotechnology, online erschienen am 16.11.2026. Verfasst von R. Grytsko. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rising antimicrobial resistance and the prohibition of prophylactic antibiotic use in livestock under EU Regulation 2019/6 have created urgent demand for alternatives capable of maintaining herd health without amplifying resistance. Nucleotides in bacterial-yeast fermented milk beverages occupy a distinctive position among such alternatives: unlike most feed additives, they act through identified receptor systems – TLR9 (bacterial CpG-DNA), purinergic P2X7 receptors (extracellular ATP) and the nucleotide salvage pathway in lymphocytes and enterocytes – justifying their classification as pharmacologically active substances. The aim of the study was to systematise the molecular mechanisms of action of a nucleotide-enriched bacterial-yeast fermented milk beverage, to consolidate field observations of its clinical efficacy in young farm animals and poultry, to compare them with contemporary randomised experimental evidence, and to develop a practical on-farm preparation protocol and speciesspecific dosing schedules. The literature search covered PubMed/MEDLINE, Scopus and Web of Science, predominantly for 2000–2025. Own field observations were conducted on farms in the Lviv and Ternopil regions in 1993–2005 in Holstein calves, weaned piglets, sows and Cobb broiler chickens, each experimental group being compared with concurrent control animals from the same farm. The beverage was prepared by a two-phase fermentation protocol and contained at least 0.8 mg/mL of nucleic acids (spectrophotometry, λ = 260 nm). Enteric disease incidence in calves fell by 35–47 %, the proportion of calves requiring antibiotic treatment decreased from 68 % to 24 %, and average daily gain improved by approximately 100 g/day. Post-weaning diarrhoea in piglets fell from 38.4 % to 11.2 % and antibiotic use by 62–71 %. Sows showed 23–31 % higher colostral IgG, and the incidence of MMA syndrome decreased from 22.4 % to 8.7 %. Broiler survival improved from 88.2 % to 94.8 % (by 6.6 percentage points), with a higher relative weight of the bursa of Fabricius, higher intestinal sIgA content and significantly enhanced vaccine responses. These findings are consistent with randomised trials conducted independently in Poland, Spain and Thailand; the main methodological limitation of the field data is the absence of blinding. Overall, the need for antibiotic treatment was reduced by 50–70 % with no adverse effects observed and at an acceptable cost. A practical on-farm preparation protocol and species-specific dosing schedules are provided. Multicentre randomised controlled trials with standardised endpoints are needed to confirm these results
Zitieren
APA
Grytsko, R. (2026). Nucleotides from bacterial-yeast fermentation as pharmacologically active feed supplements: immune mechanisms, clinical evidence and practical guidelines. Scientific Messenger of LNU of Veterinary Medicine and Biotechnology, 28(122), 10-14. https://doi.org/10.32782/nvlvet12202
Vancouver
Grytsko R. Nucleotides from bacterial-yeast fermentation as pharmacologically active feed supplements: immune mechanisms, clinical evidence and practical guidelines. Scientific Messenger of LNU of Veterinary Medicine and Biotechnology. 2026;28(122):10-14. doi:10.32782/nvlvet12202
BibTeX
@article{Grytsko2026,
author = {Grytsko, R.},
title = {Nucleotides from bacterial-yeast fermentation as pharmacologically active feed supplements: immune mechanisms, clinical evidence and practical guidelines},
journal = {Scientific Messenger of LNU of Veterinary Medicine and Biotechnology},
year = {2026},
volume = {28},
number = {122},
pages = {10--14},
doi = {10.32782/nvlvet12202}
}
EUVIMED